**Core tip:** Ubiquitin-specific protease 22 (USP22) belongs to the USPs family, which regulates cell cycle progression, proliferation, and tumor invasion. Depleted expression of USP22 has been linked to arrested cell cycle and disrupted distribution and generation of differentiated cell types in crypts and villi. However, its regulatory mechanism remains unclear. By generating models of ischemia reperfusion (I/R) injury and regulating USP22 expression levels, this study reveals that USP22 is correlated with promoting intestinal cell proliferation and accelerating intestinal tissue regeneration after intestinal I/R injury. USP22 might serve as a potential target for therapeutic development for tissue repair during intestinal I/R injury.

INTRODUCTION
============

Intestinal ischemia reperfusion (I/R) injury is a serious pathophysiological process that occurs in many clinical conditions, including mesenteric arterial thrombotic or embolic diseases, shock, major surgery, and organ transplantation\[[@B1]-[@B3]\]. Intestinal I/R injury is a common pathogenesis of many diseases and also the initial factor of systemic inflammatory response syndrome and multiple organ dysfunction syndrome, resulting in a high mortality rate in clinical practice\[[@B4]-[@B6]\]. Intestinal I/R injury can result in serious damage to the mucosa and at the same time cause barrier dysfunction, which is a chief factor contributing to intestinal I/R injury. The dysfunction of the mucosal barrier and fragile immunization has been reported to be the leading cause of serious complications and death. Intestinal I/R injury is always followed by proliferation and subsequent differentiation of intestinal epithelial cells to rebuild the proper structure of the epithelium\[[@B3],[@B7],[@B8]\]. The intestinal barrier is an epithelial monolayer and serves as the first line of defense within the intestinal lumen against any unfavorable conditions\[[@B3],[@B9]\]. It has been found that after the initiation of injury by intestinal I/R, the intestinal mucosal barrier undergoes regeneration through significant proliferation of undifferentiated progenitor cells\[[@B10]\]. However, insufficient proliferation and regeneration to fully rescue intestinal mucosal barrier function can be seen by the high mortality rate in clinical practice\[[@B11]\]. Therapeutic development of intestinal regeneration may serve as a good means to rescue those suffering from intestinal ischemia and improve patient prognosis. Currently, several studies have been focused on cell proliferation and tissue regeneration after I/R injury\[[@B12]\], but the underlying mechanisms remain largely unknown.

Ubiquitin-specific protease 22 (USP22) belongs to the largest subfamily of deubiquitinases, known as USPs, and is a conserved component of the hSAGA activating complex that takes ubiquitin from target proteins to regulate cell cycle progression, proliferation, and tumor invasion\[[@B13]-[@B16]\]. USP22 plays a pivotal role in stabilizing c-Myc, an oncogenic protein that controls the cells in the balance between proliferation and death\[[@B17],[@B18]\]. The depletion of USP22 has been reported not only to induce arrest of the G1 cell cycle in colorectal cancer cells *in vitro*\[[@B18]-[@B20]\], but also to affect the distribution and proper generation of differentiated cell types in crypts and villi\[[@B21]\]. However, the role of USP22 in intestinal damage recovery has not been investigated. To date, studies regarding USP22 function have been mostly focused on its potential in facilitating and promoting stem cell-like characteristics in various tumor types. While the knowledge of USP22 in intestinal epithelial cell proliferation may provide evidence for clinical exploration of novel therapeutic targets against intestinal I/R, its function and physiological role during the intestinal I/R process still need to be elucidated.

Based on the above background, we speculated that USP22 may participate in intestinal regeneration after I/R injury and may serve as a potential target in clinical practice. In this study, we observed for the first time the role of USP22 in intestinal regeneration during intestinal I/R injury and identified the advantages of having USP22 in intestinal epithelial cell proliferation after hypoxia/reoxygenation.

MATERIALS AND METHODS
=====================

Intestinal I/R injury animal model
----------------------------------

Thirty-five male Sprague-Dawley rats, weighing between 180 and 220 g, were randomly distributed into one sham group and four model groups with respect to the duration of reperfusion (*n* = 7 each) using a random number table. The sample size was determined by power analysis\[[@B22]-[@B24]\]. All animals were accommodated in different cages at the same proper and constant temperature and were acclimated for one week before the experiments. All animals were handled conforming to the approved protocol by the Animal Care and Use Committee of Dalian Medical University, Liaoning, China and in compliance with the National Institutes of Health guidelines. An animal model of intestinal I/R injury was developed through surgery as previously described by Megison et al\[[@B25]\]. Briefly, after identifying the superior mesenteric artery (SMA) in the midline laparotomy, the intestinal I/R injury was established by occluding the SMA with an atraumatic microvascular clamp for 60 min. Occlusion was confirmed after mesenteric pulsations ceased and the intestines became pale. Reperfusion was then performed for 3 h, 6 h, 12 h, or 24 h. The sham group was exposed to the same procedures without vascular occlusion. After being sacrificed, the ileum specimens in rats were excised by midline laparotomy.

Histology and immunohistochemical staining
------------------------------------------

After the rats were sacrificed, the specimens were excised, immediately fixed in 10% neutral buffered formalin, embedded in paraffin wax, and cut into consecutive 4-μm-thick slides. Hematoxylin and eosin (HE) staining was then performed. Chiu's scoring system was used to quantitatively determine the histological scores of the intestine\[[@B26]\]. Immunohistochemical analysis was conducted according to the manufacture's protocol. Briefly, the sections were incubated with an anti-PCNA monoclonal antibody overnight at 4 °C. While blind to the clinicopathological data of the patients, two experienced pathologists independently examined staining to determine the expression of PCNA. The number of positive cells that showed immune-reactivity in cell nuclei in the representative ten microscopic fields was counted and the percentage of positive cells was calculated.

Cell culture and hypoxia/reoxygenation model
--------------------------------------------

IEC-6 cells (normal rat small intestinal epithelial cells) were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco BRL) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. All cells were cultured in an incubator maintained at 37 °C with 5% CO~2~. To imitate a hypoxic environment, we incubated the cells in a microaerophilic system (Thermo Fisher Scientific 8000, Marietta, GA, United States) containing 1% O~2~ and 5% CO~2~ balanced with 94% N~2~ gas for 6 h. Reoxygenation was achieved later by culturing the cells under a normoxic environment.

USP22 knockdown and overexpression
----------------------------------

IEC-6 cells were transfected in a 6-well plate with USP22 siRNA (si-USP22, 50 nmol/L) or unspecific scrambled siRNA (GenePharma, Shanghai, China) using a Lipofectamine 3000 Reagent (Invitrogen L3000075, Shanghai, China). Target sequence for si-USP22 is as follows: Sense (5'-3') GCUACCAAGAG UCCACAAA; antisense (5'-3') UUUGUGGACUC UUGGUAGC. The negative control sequence is as follows: Sense (5'-3') UUCUCCGAACG UGUCACGU; antisense (5'-3') ACGUGACACGU UCGGAGAA. The ratio of siRNA and Lipofectamine 3000 was 100:3.75 (pmol:μL). For overexpression of USP22, the overexpression plasmid designed and synthesized by GenePharma was transfected into IEC-6 cells using a Lipofectamine 3000 Reagent. The cells were later cultured for 48 h post-transfection for further analysis.

Western blot analysis
---------------------

Harvested cells and proteins from the intestinal samples were extracted according to the manufacturer's instructions (KeyGEN Biotech, Nanjing, Jiangsu Province, China). Equal concentrations of protein were separated by SDS-PAGE and then transferred onto polyvinylidene fluoride membranes. Subsequently, the membranes were incubated at 4 °C overnight with a primary antibody against USP22 (1:1000; Proteintech 55110, Wuhan, Hubei Province, China), β-actin (1:1000; ZSGB-BIO PR-0255, Beijing, China), or Cyclin D1 (1:500; Proteintech 12363), followed by incubation with a horseradish peroxidase (HRP)-conjugated secondary antibody (1:1000; ZSGB-BIO ZDR-5306). Enhanced chemiluminescence was used to visualize and quantify the immunoreactive protein bands. The experiment was repeated in triplicate.

Cell viability assay
--------------------

Cell Counting Kit-8 (CCK-8; Dojindo Molecular Technologies CK04, Inc., Tokyo, Japan) was used to measure ratios of survival cells according to the manufacturer's instructions. Briefly, approximately 3500 IEC-6 cells per well were seeded and received proper treatment in 96-well plates followed by addition of a CCK-8 solution to each well at a 1/10 dilution. After a one-hour incubation at 37 °C, the cells alive in each well are able to form formazan and cell viability could be evaluated by detecting the absorbance at 450 nm in each well using a microplate reader (Biotec, United States).

Cell cycle analysis
-------------------

A Cell Cycle and Apoptosis Analysis Kit (Beyotime C1052, Shanghai, China) was used to analyze cell cycle distribution according to the manufacturer's instructions. Briefly, transfected IEC-6 cells were seeded and fixed with 70% ethanol in 6-well plates overnight at 4 °C. The cells were washed twice and resuspended with a phosphate buffered saline (PBS) solution. Propidium iodide (GeneChem, Shanghai, China) and ribonuclease were added to PBS and cells were incubated for 30 min at 37 °C. A FACSCalibur flow cytometer (BD, United States) was used to detect cell cycle. The experiment was repeated in triplicate, and each experiment had two specimens.

Statistical analysis
--------------------

All data are presented as the mean ± standard deviation (SD). SPSS 19.0 statistical software package (SPSS Inc., Chicago, IL, United States) was used to analyze the data. GPower 3.1 software package was used to determine the adequate sample size (significance level *α* = 0.05; desired statistic power 1-*β* = 0.8). Student's *t*-test was used to determine significant differences between the two groups, and one-way ANOVA was adopted among multiple groups. Differences with a *P*-value less than 0.05 were considered statistically significant.

RESULTS
=======

USP22 expression is positively correlated with cell proliferation and tissue regeneration after intestinal I/R injury in rats
-----------------------------------------------------------------------------------------------------------------------------

To evaluate the histopathological change of the intestinal mucosal barrier and its function after intestinal I/R injury in rats, HE staining and Chiu's scoring were performed. It is evident that small intestinal villi were damaged during reperfusion (Figure [1A](#F1){ref-type="fig"}) and that I/R injury led to significant dysfunction of the small intestine with mucosal injury (Figure [1B](#F1){ref-type="fig"}). To investigate USP22 levels after intestinal I/R injury, we observed that USP22 was progressively downregulated from 0 h to 6 h in the early phase of reperfusion, whereas it reached its trough value at 6 h and recovered in the late phase of reperfusion (6-24 h). Changes in USP22 expression during the whole process were negatively correlated to corresponding Chiu's scores.

![Ubiquitin-specific protease 22 is positively correlated with cell proliferation and tissue regeneration after ischemia reperfusion injury. Anesthetized rats were subjected to 60 min of intestinal ischemia followed by 3, 6, 12, or 24 h of reperfusion and tissues were harvested at the end of reperfusion. A: Intestinal tissue sections of the experimental groups were stained with HE (200×, bars represent 100 μm); B: Intestinal tissues in injury was scored histopathologically according to a scoring system (Chiu's score); C: Representative Western blot demonstrating the expression of USP22 in tissues from the experimental groups (*n* = 3); D: Immunohistochemical staining for PCNA was used for intestinal tissue sections of the experimental groups (400×, bars represent 50 μm); E: Quantitative analyses for immunohistochemical staining. The arrows show brown positive nuclei of proliferating intestinal cells in the crypt area of the intestinal gland; F: Representative protein levels of Cyclin D1 (*n* = 3) were demonstrated by Western blot. The results are presented as the mean ± SD. ^b^*P* \< 0.01 *vs* sham. USP22: Ubiquitin-specific protease 22; PCNA: Proliferating cell nuclear antigen.](WJG-25-824-g001){#F1}

Since PCNA is critically linked to DNA synthesis and plays a vital role in cell proliferation, the level of PCNA can, to some extent, mirror the level of proliferation. Thus, the proliferative activity of the intestinal mucosa during reperfusion at each given time point was assessed by immunohistochemical staining for PCNA (Figure [1D](#F1){ref-type="fig"} and E). It is intuitive that the level of PCNA was positively correlated with that of USP22. Furthermore, on account of being the main marker during the G1 phase of the cell cycle, Cyclin D1 expression level was also investigated. As shown in Figure [1F](#F1){ref-type="fig"}, Cyclin D1 levels were consistent with those of PCNA and USP22. Therefore, our results demonstrated that USP22 is positively correlated with intestinal regeneration and might play a vital role after I/R injury *in vivo*.

USP22 correlates with the proliferative activity of IEC-6 cells after hypoxia/reoxygenation injury
--------------------------------------------------------------------------------------------------

In line with the induction of USP22 during intestinal I/R *in vivo*, IEC-6 cells exposed to different time durations (3, 6, 12, or 24 h) of reoxygenation after 6-h hypoxia treatment were analyzed. The protein expression levels of USP22 were measured (Figure [2A](#F2){ref-type="fig"}) and IEC-6 cell proliferation was assessed (Figure [2B](#F2){ref-type="fig"} and C). USP22 expression was shown to be positively associated with Cyclin D1 and cell viability of IEC-6 cells in a time-dependent pattern. Thus, our results demonstrated that USP22 directly correlates to the proliferative and regenerative activity of IEC-6 cells after hypoxia/reoxygenation injury.

![Ubiquitin-specific protease 22 correlates with the proliferative activity of IEC-6 cells after hypoxia/reoxygenation. IEC-6 cells were subjected to 6 h of hypoxia followed by 3, 6, 12, or 24 h of reoxygenation. A: Representative Western blot demonstrating the expression of USP22 in tissues from the experimental groups (*n* = 3); B: Representative Western blot demonstrating the expression of Cyclin D1 in tissues from the experimental groups (*n* = 3); C: CCK-8 was used to examine cell proliferation and viability at the indicated time points (*n* = 6). The results are presented as the mean ± SD. ^a^*P* \< 0.05 *vs* the control group; ^b^*P* \< 0.01 *vs* the control group. USP22: Ubiquitin-specific protease 22; CCK-8: Cell Counting Kit-8.](WJG-25-824-g002){#F2}

USP22 knockdown inhibits cell proliferation and induces cell cycle arrest in IEC-6 cells after hypoxia/reoxygenation injury
---------------------------------------------------------------------------------------------------------------------------

As the expression levels of USP22 changed during intestinal regeneration after I/R, the effect of silencing USP22 on the proliferation of IEC-6 cells was subsequently investigated. USP22 knockdown (Figure [3A](#F3){ref-type="fig"}) by using siRNA (si-USP22) dramatically decreased USP22 level and, in parallel, the levels of cyclin D1 and of cell vitality (Figure [3B](#F3){ref-type="fig"}) and viability (Figure [3C](#F3){ref-type="fig"}) compared with the negative control. Using flow cytometry, we elucidated how USP22 knockdown correlated with inhibited cell proliferation after hypoxia/reoxygenation by observing the cell cycle. We found that si-USP22-treated cells had a much higher percentage in G1 and significantly lower numbers in S phase than the counterparts of the negative control cells (Figure [3D](#F3){ref-type="fig"} and E). Thus, our results demonstrated that silencing USP22 closely correlates with IEC-6 cell proliferation potential after hypoxia/reoxygenation injury by stopping the cells entering S phase.

![Ubiquitin-specific protease 22 knockdown inhibits cell proliferation and induces cell cycle arrest in IEC-6 cells after hypoxia/reoxygenation. IEC-6 cells were transfected with USP22 siRNA or unspecific scrambled siRNA and then subjected to hypoxia/reoxygenation or left untreated. A: Western blot analysis for USP22 and β-actin in ICE-6 cells transfected with USP22 siRNA and control siRNA (*n* = 3); B: Western blot analysis for Cyclin D1 and β-actin in ICE-6 cells transfected with USP22 siRNA and control siRNA (*n* = 3); C: CCK-8 was used to examine cell viability at the indicated time points (*n* = 6); D and E: FACSCalibur analysis of the percentages of cells in the G1, G2, and S phases at 24 h of reoxygenation after 6 h of hypoxia (*n* = 3). The results are presented as the mean ± SD. ^a^*P* \< 0.05 *vs* the control group; ^b^*P* \< 0.01 *vs* the control group. USP22: Ubiquitin-specific protease 22; CCK-8: Cell Counting Kit-8.](WJG-25-824-g003){#F3}

USP22 overexpression promotes cell proliferation in IEC-6 cells after hypoxia/reoxygenation injury
--------------------------------------------------------------------------------------------------

We further examined the effect of USP22 overexpression on intestinal cell proliferation by transfection with a USP22 expression plasmid. It can be seen in Figure [4A](#F4){ref-type="fig"} that USP22 was significantly overexpressed and that cell viability was dramatically increased (Figure [4B](#F4){ref-type="fig"} and C). By observing the cell cycle, we investigated how USP22 overexpression correlated with activated cell proliferation after hypoxia/regeneration. We found that USP22-overexpressing cells had a much lower number of cells in G1 phase and significantly more cells in S phase than the negative control cells (Figure [4D](#F4){ref-type="fig"} and E). Thus, our results demonstrated that USP22 overexpression may promote cell proliferation and viability in this process.

![Ubiquitin-specific protease 22 overexpression promotes cell proliferation in IEC-6 cells after hypoxia/reoxygenation. IEC-6 cells were transfected with a USP22 overexpression plasmid or a negative control plasmid and then subjected to hypoxia/reoxygenation or left untreated. A: Western blot analysis for USP22 and β-actin in ICE-6 cells transfected with IEC6-USP22 and IEC6-Control (*n* = 3); B: Western blot analysis for Cyclin D1 and β-actin in IEC-6 cells transfected with IEC6-USP22 and IEC6-Control (*n* = 3); C: CCK-8 assay was used to examine cell viability at the indicated time points (*n* = 6); D and E: FACSCalibur analysis of the percentages of cells in the G1, G2, and S phases at 24 h of reoxygenation after 6 h of hypoxia (*n* = 3). The results are presented as the mean ± SD. ^a^*P* \< 0.05 *vs* the control group; ^b^*P* \< 0.01 *vs* the control group. USP22: Ubiquitin-specific protease 22; CCK-8: Cell Counting Kit-8.](WJG-25-824-g004){#F4}

DISCUSSION
==========

This study identified progressive downregulation of USP22 that occurred at the early phase of reperfusion (0-6 h) in intestinal I/R or hypoxia/reoxygenation injury *in vivo* or *in vitro*. Whereas the expression of USP22 reached its trough value at 6 h, it recovered during 6-24 h in long-term reperfusion. The time-varying property of USP22 was in accordance with the histology and Chiu's scores in different time point groups in intestinal I/R rats. Thus, it is evident that USP22 was involved in promoting crypt cell proliferation and in facilitating intestinal tissue regeneration after intestinal I/R injury. Downregulation of USP22 was closely correlated with reduced Cyclin D1 and cell viability with accumulation of cells in the G1 phase of the cell cycle and being stopped from entering S phase. Meanwhile, we observed increased levels of Cyclin D1 and cell viability and facilitated cell cycle in USP22-overexpressing intestinal cells. Our findings indicated that USP22 may play a pivotal role in intestinal cell proliferation and tissue repair after intestinal I/R injury.

USP22 serves as a key subunit of the hSAGA complex that can regulate proliferation-related gene expression, such as c-Myc and MAPK\[[@B15],[@B19],[@B27],[@B28]\]. USP22 can enhance cell growth and promote cell cycle progression in some cell lines\[[@B14]\]. USP22 can also suppress apoptosis and promote cell proliferation by antagonizing p53 function through the regulation of SIRT1\[[@B29],[@B30]\]. It was also confirmed *in vivo* by Kosinsky et al\[[@B21]\] that villous goblet cells are significantly increased in a global USP22 reduction mouse model, where goblet cells are crucial for intestinal barrier function, tissue repair and healing\[[@B31],[@B32]\]. This evidence suggested that USP22 positively correlated with the level of regeneration; thus, it may play a pivotal role in promoting tissue repair. We observed PCNA levels during reperfusion after intestinal I/R since PCNA is the widely recognized mediator of proliferation levels\[[@B33]\]. With the time-dependent proliferative activity during intestinal I/R (Figure [1D](#F1){ref-type="fig"}-F), a powerful indication can be made that the severity of mucosal damage had a negative correlation to the corresponding proliferative activity (Figure [1C](#F1){ref-type="fig"}, E, and F), which is in accordance with our former research\[[@B7]\]. Interestingly, a positive relationship with proliferative levels was found when investigating the level of USP22 both *in vivo* and *in vitro* (Figures [1A](#F1){ref-type="fig"}, 2A). Thus, the assumption was made that USP22 is involved in the regeneration of intestinal I/R injury. Accordingly, we adopted a USP22 knockdown and overexpression transfection technique in intestinal cells to confirm this hypothesis.

Cyclin D1 is needed in the transition from G1 to S phase in the cell cycle and thus serves as a vital target for proliferative signals\[[@B34]\]. Being a crucial regulator of the cell cycle, Cyclin D1 is responsible for inducing the G1/S transition. It forms a complex that targets a transcriptional factor by binding with different cyclin-dependent kinases\[[@B35]\]. Therefore, downregulation of Cyclin D1 can cause cell cycle arrest in the G1/S phase\[[@B36]\]. We found that the alteration of Cyclin D1 shared the same pattern as USP22 expression levels and the proliferative activity as indicated by PCNA expression both *in vivo* and *in vitro*. As we investigated deeper and more precisely *in vitro* by means of flow cytometry, we observed the arrested cell cycle progression of IEC-6 cells in S phase in the USP22 knockdown group when compared to the hypoxia/reoxygenation group (*P* \< 0.05). Moreover, the opposite tendency of Cyclin D1 and cell viability was also observed in the USP22 overexpression group. Thus, this finding led to the conclusion that USP22 is positively correlated with increased potential of cell proliferation after hypoxia/reoxygenation injury. In addition, the mechanism of USP22 on promoting cell cycle progression in colorectal cancer has been reported recently, which further confirmed our results\[[@B37]\].

In our present study, we focused on the effect of USP22 on intestinal damage repair in I/R injury and found that the regulatory effect of USP22 on I/R injury could be potentially utilized in the future. To the best of our knowledge, no prior study has investigated USP22 expression and its pro-regenerative properties in intestinal I/R injury. Some studies showed the association of USP22 with progression and therapeutic failure of colorectal cancer, which could be valuable for consultation in further study on intestinal I/R injury and cancer research\[[@B38],[@B39]\].

There were limitations in our study. Although the *in vitro* experiments implied a direct link between USP22 and regeneration, the *in vivo* study should be better designed to imply causation and biological linkage in our further study. In addition, a great number of clinical samples are needed to prove that the conclusion is also applicable for human beings. Furthermore, observation has been made that USP22 was globally reduced in a mouse model and that goblet cells were abundant\[[@B21]\]. While goblet cells are known as mucus secreting cells, they also share gate-keeping roles with epithelial cells and are indispensable in regulating innate immune function\[[@B40],[@B41]\]. Other studies also confirmed that antibodies were secreted within the mucus from intestinal epithelial goblet cells\[[@B31]\]. Thus, the role of USP22 in intestinal damage recovery needs further investigations and we would not only adopt USP22 knockout mouse models but also investigate more precisely the association of USP22 with immune barrier and the underlying mechanisms in intestinal I/R injury.

In conclusion, this study demonstrated that USP22 was involved in intestinal epithelial cell proliferation and tissue regeneration after hypoxia/reoxygenation or I/R injury. Our study revealed a novel role for USP22 in intestinal regeneration after I/R injury. Therefore, targeting USP22 signaling may increase the therapeutic potential for intestinal I/R injury. In our future research, we will try to elucidate the internal mechanisms of USP22 signaling in intestinal regeneration after I/R injury.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Ubiquitin-specific protease 22 (USP22) is a novel member of the USPs subfamily, acting as a regulator of cell cycle progression, proliferation, and tumor invasion. Decreased expression of USP22 has been identified to contribute to arrested cell cycle and disrupted generation of differentiated cell types in crypts and villi. However, the regulatory mechanism of USP22 remains unclear. Therefore, elucidation of the underlying mechanism may help to improve the tissue repair in intestinal ischemia reperfusion (I/R) injury.

Research motivation
-------------------

It is necessary to explore whether USP22 is correlated with increased potential of cell proliferation and tissue regeneration in intestinal I/R injury. Recent studies have demonstrated that insufficient proliferation and regeneration of fully rescuing intestinal mucosal barrier function could be witnessed by the high mortality rate in clinical practice. Moreover, the potential role of USP22 in cell growth, cell cycle progression, and generation of differentiated cell types has also been reported in crypts and villi. These findings give us a good lead for further study regarding the mechanism of USP22 regulation during intestinal I/R injury.

Research objectives
-------------------

In the previous study, we investigated the effect of USP22 on intestinal cell proliferation and regeneration after intestinal I/R injury both *in vivo* and *in vitro* by gain- and loss-of-function approaches. Our study provides significant insight into the signalling mechanism of USP22 during intestinal I/R injury that may contribute to the future investigation of more effective therapies in clinical practice.

Research methods
----------------

Experiments using an animal model and *in vitro* model in rats and cells to better elucidate the pathophysiological process of intestinal I/R injury. Hematoxylin and eosin staining and Chiu's scoring system were used to demonstrate the intestinal tissue injury histopathologically. Immunohistochemical staining for PCNA was carried out to display and observe positive nuclei of proliferating intestinal cells. Gene silencing or transfection was conducted to construct relatively stable USP22-depleted or -expressed cells to complete the following functional studies. A series of *in vitro* experiments, such as Western blot, Cell Counting Kit-8, and cell cycle analysis, were performed to explore the effect of USP22 on cell proliferation.

Research results
----------------

Experiments *in vivo* showed the correlation between USP22 and intestinal regenerative activity of intestinal cells after intestinal I/R injury. The results of *in vitro* experiments showed a direct positive correlation of USP22 with cell proliferation and cell cycle progression of intestinal cells after hypoxia/reoxygenation injury. This study could be valuable for consultation in further study on intestinal I/R injury and be potentially utilized in therapeutic enhancement in clinical practice. Limitations did exist that the *in vivo* study should be better designed to imply causation and biological linkage and USP22 knockout mouse models would be helpful. Clinical samples are also needed to better suit the application on human beings.

Research conclusions
--------------------

USP22 plays a positive role in intestinal epithelial cell proliferation and tissue regeneration in intestinal I/R injury. This study reveals a novel role for USP22 in intestinal regeneration after I/R injury. Targeting USP22 may increase the therapeutic potential for intestinal I/R injury in clinical practice.

Research perspectives
---------------------

Our study illuminates the role of USP22 in intestinal epithelial cell proliferation and tissue regeneration in intestinal I/R injury. Other researchers have reported the abundant mucus secreting goblet cells in a USP22 globally reduced mouse model. While goblet cells are also one of indispensable parts in regulating innate immune function, further investigation is needed.
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